Normal development of fetal hepatic haematopoiesis during the second trimester of gestation is upregulated by fibronectin expression in the stromal cells of the portal triads

D. Tamiolakis, I. Venizelos, S. Nikolaidou and T. Jivanakis

Department of Cytology, General Hospital of Chania, Crete, Greece. 1Department of Histology-Embryology, Democritus University of Thrace, Medical Faculty, Dragana, Alexandroupolis, Thrace, Greece

ABSTRACT

Objective: In midtrimester fetuses the principal site of hematopoiesis is the liver. In hematopoietic organs, stromal cells such as fibroblasts, epithelial cells, and macrophage-like cells develop networks to maintain hematopoiesis, i.e. hematopoietic stem cell self-renewal, proliferation, and growth, by interaction with hematopoietic progenitor cells. ECM glycoproteins produced by the stromal cells are known to play a critical role in the regulation of cell growth and differentiation. Numerous soluble and membrane-bound factors directly regulating hematopoiesis have been documented, but little is known about fetal hepatic stromal cell activity and stromal extracellular matrix protein-fibronectin, on fetal hepatic haematopoiesis. The binding of late stage erythroid cells to fibronectin has been well characterized and is believed to be critical for the terminal stages of erythroid differentiation. The intention of this article is to determine the role of fibronectin in fetal hepatic hematopoietic proliferation and differentiation in different stages of development.

Material and method: We examined and compared the immunohistochemical expression of fibronectin in the hepatic stromal portal fields in the 1st, 2nd, and 3rd trimester of gestation respectively, in relation to the appearance of CD34 progenitor hematopoietic, stromal progenitor and vascular endothelial positive cells.

Results: Our results demonstrated a quantitative difference in the second trimester of gestation concerning the expression of fibronectin in the connective tissue stroma of the hepatic portal fields over the equivalent expression of the protein in the first (p < 0.0001, t-test) and third trimester (p < 0.0001, t-test). Similar changes in the above period were found concerning the expression of CD34 during the second trimester of gestation, over the first (p < 0.0001, t-test) and third trimesters (p < 0.0001, t-test), suggesting a direct involvement of fibronectin in the sustaining of hematopoietic activity.
**INTRODUCTION**

Fibronectin (FN) is a multidomain adhesive glycoprotein found in blood and interstitial connective tissue. It interacts with multiple cell surface receptors and plays an important role in the regulation of anchorage-dependent cell growth, cell migration, differentiation, gene expression, tumor development and metastasis, embryogenesis, angiogenesis, and wound healing (1-5).

The reason why the liver is the major hematopoietic site during fetal life is not clear. That the bone marrow is not yet mature this period and that fetal hematopoietic stem cells (HSCs) present specific characteristics do not explain the specific HSC homing to the fetal liver tissue. Stromal cells of the hepatic stromal triads synthesize growth factors, cell adhesion molecules, and extracellular matrix (ECM) molecules which are essential for the establishment of a microenvironment supportive of hematopoietic cell growth and differentiation (6). Fibronectin, a multifunctional ECM glycoprotein found in the fetal hepatic parenchyme (hepatic stromal cells), has been shown to influence the adhesion, migration, growth, and differentiation of many cell types, including hematopoietic cells (7). Interactions of erythroid cells with FN are believed to be essential for erythropoiesis, particularly for the terminal stages of erythroid differentiation (8).

Human hematopoiesis is initiated in the yolk sac during the 3rd week of development (9). The earliest hematopoietic cells (CD34+, CD45+) can be detected during the 5th week of gestation in the aorta-gonad-methanepros region. These cells form compact clusters in close association with the ventral wall of the dorsal aorta (9,10) and then eventually seed in the fetal liver and spleen (10). In contrast, hematopoiesis in the bone marrow commences only about the 12th week of gestation (9). The liver becomes the predominant hematopoietic site from the 6th week of gestation. Bone marrow takes over after birth.

Erythropoiesis comprises the major part of fetal liver hemopoiesis. Most studies performed by light and electron microscopy have shown early development of erythropoiesis in hepatocyte “niches”, with continuing maturation within the sinusoids. Cells of erythroid lineage are present in circumscribed clusters in the hepatic parenchyma, which is the place of early erythropoietic development and along the sinusoids where further maturation takes place. Myelomonocytic cells, during the first trimester of gestation, are located mostly in the mesenchymal tissue of the portal triads. In the second trimester the distribution pattern is somewhat different. No main localization is seen in portal spaces, but scattered cells in liver parenchyma and sinusoids are visible. Lymphoid cells are present in small numbers in all stages. These cells are partly scattered throughout the sinuses but, surprisingly, from 16 week onwards, a considerable number of lymphoid cells are also observed in the perivascular connective tissue in the portal triads and around the central veins, which is similar to the localization of myelopoiesis.

The availability of a broad range of monoclonal antibodies (Mabs) recognizing antigens present on cells of different haemopoietic lineages has extended the possibilities for an accurate description of the cells present in these separate lineages and their precursors during different stages of human embryonic and fetal development.

CD34 antigen is a single chain transmembrane glycoprotein with a molecular weight of 110 KD. The CD34 protein is selectively expressed on human lymphoid and myeloid haematopoietic progenitor cells. The CD34 protein is also expressed on vascular endothelium.

Our study gives insight into mechanisms of augmentation of hepatic hematopoiesis with fibronectin expression during the second trimester of development.

**MATERIAL AND METHODS**

We studied 15 cases of hepatic fetal specimens in different stages of development (1st, 2nd, and 3rd trimester) obtained after voluntary abortion due to leiomyoma (five...
samples), to implantation of the fetus in the region of the internal os resulting in placenta previa (six samples), and to endometriosis-adenomyosis (four samples). All cases were chosen from specific time of development (2nd month: five cases, 5th month: five cases and 8th month: five cases respectively). The study was executed in harmony with the guidelines for the analysis of fetal cells and tissues and approved by the Ethics Committee of the General Hospital of Alexandroupolis. Tissue samples were processed for paraffin section immunophenotyping and stained using the monoclonal antibodies against fibronectin by DAKO and CD34 (NCL-END) by Novocastra. Detection of the antigens in formalin-fixed tissue specimens required antigen-demasking protocols prior to application of antibodies. In most instances this was accomplished using high-pressure cooking (11) in 10 mM citrate buffer at pH 6.0. Specifically bound antibodies were made visible with the alkaline phosphatase-anti-alkaline phosphatase (APAAP) technique (12) using FastRed as chromogen.

The immunostained sections were examined with a X 40 objective and the distribution of fibronectin and NCL-END within the cell was recorded. Every stained cell was scored as positive regardless of staining intensity. To count the number of cells with fibronectin and CD34 stainings, a 10 X 10 square calibrated grid was inserted into the eyepiece of an Olympus BX40 binocular microscope.

Five-to-ten fields were examined for each section, and at least 1,000 cells were scored, depending on cellularity. The percentage of positive cells was recorded as the relevant indices.

\[
\text{Fibronectin index} = \frac{\text{no of positive cells}}{\text{no total (positive + negative cells)}}
\]

\[
\text{CD34 index} = \frac{\text{no of positive cells}}{\text{no total (positive + negative cells)}}
\]

The indices ranged from 0-100%, with a mean of 18%. The mean index was evaluated in three ranges: low index (under 18%), grade I; moderate index (from 18 to 50%), grade II; and high index (from 51 to 100%), grade III.

We used the parametric method t-test for the statistical analysis of our results because our sample values (cells/mm²) in each case had a normal distribution.

RESULTS

The sections were examined independently by two observers, and positive cellular staining for fibronectin and CD34 antibodies were manifested as fine red cytoplasmic granularity and/or surface membrane expression.

Hepatic portal triad stromal cells expressed fibronectin in 7 of 15 fetuses-cases during the first trimester (46.66%) (32.75 ± 1.91 cells/mm²), in all 15 cases during the second trimester (100%) (48.61 ± 4.43 cells/mm²) and in 8 of 15 cases during the third trimester (53.33%) (29.37 ± 3.29 cells/mm²).

Progenitor hematopoietic cells, stromal progenitor cells, and vascular endothelial cells expressed CD34 in 10 of 15 fetuses-cases during the first trimester (66.66%) (55.41 ± 3.12 cells/mm²), in all 15 cases during the second trimester (100%) (67.93 ± 4.35 cells/mm²), and in 13 of 15 cases during the third trimester (86.66%) (101.46 ± 6.76 cells/mm²).

Our results demonstrated a statistically significant difference in the second trimester of gestation concerning the expression of fibronectin in the connective tissue stroma of the hepatic portal fields over the equivalent expression of the protein in the first (p < 0.0001, t-test) and the third trimester (p < 0.0001, t-test). Similar changes in the above period were found concerning the expression of CD34 over the first (p < 0.0001, t-test) and the third trimester (p < 0.0001, t-test) suggesting a direct involvement of fibronectin in the sustaining of hematopoietic activity.

Of 7 fetuse-cases with positive fibronectin expression during the first trimester, 5 were scored as grade I, and 2 as grade III. Of 15 fetuse-cases with positive fibronectin expression during the second trimester, 4 were scored as grade I, 9 as grade II, and 2 as grade III. Immunohistochemical control for fibronectin is shown in figure 1; there is a strong reactivity with the stromal cells of the hepatic portal triads. Of 8 fetuse-cases with positive fibronectin expression during the third trimester, 4 were scored as grade I, 2 as grade II, and 2 as grade III.

Of 10 fetuse-cases with positive CD34 expression during the first trimester, 5 were scored as grade I, 3 as grade II and 2 as grade III. Of 15 fetuse-cases with positive CD34 expression during the second trimester, 3 were scored as grade I, 7 as grade II, and 5 as grade III. Immunohistochemical control for CD34 is shown in figure 2: there is a strong reactivity with the progenitor hematopoietic stem cells, progenitor stromal cells and endothelial cells of the vessels of the hepatic portal triads.

Fig. 1. Fetal hepatic hematopoiesis during the second trimester of gestation. Immunohistochemical control for fibronectin. Immunostain (red labeled cells) X250.
hematopoietic progenitor cells can grow in suspension, which, under physiological conditions, may regulate in- and therefore can bypass this requirement, they have a interaction with locally available growth factors.

A hematopoietic microenvironment, early progenitors are maintained in specific compartmentalized niches, where they interact with other cell types and components of the extracellular matrix (18,19). The microenvironment has been reported to influence survival, proliferation, and differentiation (20,21). More recently, it has been suggested that the primary function of these extrinsic signals, including growth factors, is to support the survival and development of committed cells, whereas lineage commitment can be attributed to cell intrinsic mechanisms (14,15,17,22). Overall, it appears that the regulation of hematopoiesis is the result of multiple processes involving cell-cell and cell-extracellular matrix interactions, the action of specific growth factors and other cytokines, as well as intrinsic modulators of hematopoietic development.

In most cells, adhesion is an essential process in the control of growth and differentiation and, although hematopoietic progenitor cells can grow in suspension and therefore can bypass this requirement, they have a close association with their stromal extracellular matrix which, under physiological conditions, may regulate interactions with locally available growth factors.

Blood cell formation is controlled by a complex set of events, including interactions between ECM and hematopoietic cells (23). Multiple cell types interact within a confined space in hematopoietic organs to deliver and receive critical signals for proliferation and differentiation. Yokota et al. showed that FN augments in vitro and in vivo growth of hematopoietic stem cells (24). Treatment of purified human CD34+ cells with FN increased the number of colonies of granulocyte-macrophage colony-forming units (CFU-GM), erythroid burst colony-forming units (BFU-E), and mixed erythroid-myeloid colony-forming units (CFU-GEMM). Increased number of CFU-Blast colonies was also observed when EML-C1 cells (a murine multipotent cell line) were pre-treated with FN (24). Therefore, FN seemed to promote colony formation of both committed and uncommitted progenitors, and these effects of FN were seen on a wider stage of differentiation than that reported by Weinste et al. (25).

Several studies have shown that ligation of FN to integrins stimulates a variety of signaling events, including tyrosine phosphorylation, cytoplasmic alkalization, calcium influx, accumulation of cytoskeletal molecules at sites of cell adhesion, and altered gene expression (26). Attachment of epithelial and endothelial cells to ECM is essential for their survival both in vitro and in vivo because they undergo apoptosis by the inhibition of these interactions (27). In addition, several lines of evidence suggest that signal transduction events through integrin ligand engagement are involved in the suppression of apoptosis in anchored cells. For example, attachment of epithelium to ECM via integrins regulated expression of interleukin 1 beta (IL-1β) converting enzyme, a protein associated with apoptosis (28). Apoptosis of detached endothelial cells was suppressed by the addition of sodium vanadate, a protein tyrosine phosphatase inhibitor (29). Among the signals via integrins, pp125 focal adhesion kinase (pp125FAK) is particularly of interest because constitutive activation of pp125FAK was sufficient to rescue an epithelial cell line, Madin-Darby Canine Kidney (MDCK) cells, from apoptosis. Moreover, injection of an anti-pp125FAK antibody into rounded fibroblasts resulted in the rapid onset of apoptosis. It is also known that pp125FAK directly associates with β subunit of integrins, and its tyrosine phosphorylation and kinase activity are upregulated by the binding of FN to integrins (30). It seems it would be of interest to evaluate roles of pp125FAK in apoptosis of EML-C1 cells, a multipotent hematopoietic cell line. Further analysis will be necessary to reveal the signal transduction pathway and structural basis of FN for promoting cell survival and growth.

All types of hematopoietic cells derive from a small pool of immature uncommitted progenitor cells. During the past few decades the phenotype of the hematopoietic progenitors has been analyzed in detail. The first "precursor cell antigen" to be described was HPCA-1 (CD34). This antigen is expressed on (almost) all types of hematopoietic progenitors. However, CD34 is also expressed on stromal cell progenitors and even on vascular endothelium. Fibronectin, one of the components of ECM molecules,
plays an important role in the regulation of hematopoietic differentiation.

The mechanism(s) of action of fibronectin on hematopoietic stem cell and microenvironment remain to be determined; however, fibronectin may possibly act by increasing binding of hematopoietic cells to stromal cells and by increasing the utilization of hematopoietic growth factors by the stem cells cooperating with other ECM molecules.

In our series: a) the comparative study of the quantitative percentage of fibronectin expression at 1st, 2nd and 3rd trimester of gestation showed a statistically significant difference in the number of stromal cells in the portal triads of the hepatic parenchyma during the second trimester over the first (p < 0.0001, t-test) and third trimesters (p < 0.0001, t-test); and b) the comparative study of the quantitative percentage of CD34 for the identification of progenitor hematopoietic cells, stromal progenitor cells, and vascular endothelial cells at 1st, 2nd and 3rd trimester of gestation showed a statistically significant difference in the number of the relevant cells of the hepatic parenchyma during the second trimester over the first (p < 0.0001, t-test) and third trimesters (p < 0.0001, t-test).

Our results imply that the expression of fibronectin in higher amounts during the second trimester of gestation provides evidence that this specific extracellular matrix glycoprotein induces the hematopoietic progenitor cell proliferation and differentiation in the fetal liver.

REFERENCES